Nutex shares fell 6.8% after earnings, as investors likely focused on declining year-to-date revenue and adjusted EBITDA and management’s disclosure that physician-fee collections were slightly weaker than hospital collections in Q3. Higher patient volumes and cash flow offered support, but the call did not provide a clear near-term outlook to offset those concerns.
- First-nine-month revenue fell 11% year over year to $644.9 million; adjusted EBITDA declined 13% to $211.4 million.
- Net income attributable to Nutex rose 159% to $152.9 million, while management cited lower earn-out and arbitration-related costs as contributors.
- Hospital visits increased 10.2% to 154,300 in the first nine months; same-hospital growth was 6.3%.
- Operating cash flow rose 6% to $188.1 million, and cash on hand increased to $249.9 million from $185.6 million at year-end 2025. Net long-term debt rose to $34.2 million from $29.2 million.
- Management attributed much of the revenue and EBITDA decline to uneven prior-year revenue recognition, but also said physician-fee collections were slightly down relative to hospital collections in Q3 and that it was monitoring the trend.
Community Discussion